1,608 Shares in Amgen Inc. $AMGN Purchased by Income Insurance Ltd

Income Insurance Ltd purchased a new position in Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, Holdings Channel reports. The fund purchased 1,608 shares of the medical research company’s stock, valued at approximately $526,000.

A number of other hedge funds have also made changes to their positions in the company. West Family Investments Inc. raised its holdings in shares of Amgen by 1.1% during the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after acquiring an additional 30 shares during the last quarter. Viawealth LLC raised its holdings in shares of Amgen by 0.4% during the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock valued at $2,023,000 after acquiring an additional 30 shares during the last quarter. LOM Asset Management Ltd raised its holdings in shares of Amgen by 1.2% during the third quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock valued at $721,000 after acquiring an additional 30 shares during the last quarter. Smith Salley Wealth Management raised its holdings in shares of Amgen by 0.3% during the fourth quarter. Smith Salley Wealth Management now owns 10,786 shares of the medical research company’s stock valued at $3,530,000 after acquiring an additional 30 shares during the last quarter. Finally, Evergreen Private Wealth LLC raised its holdings in shares of Amgen by 4.0% during the fourth quarter. Evergreen Private Wealth LLC now owns 785 shares of the medical research company’s stock valued at $257,000 after acquiring an additional 30 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on AMGN. Wall Street Zen cut Amgen from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Wells Fargo & Company increased their target price on Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a report on Thursday, March 19th. TD Cowen reissued a “buy” rating on shares of Amgen in a report on Wednesday, February 4th. Erste Group Bank reissued a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. Finally, Truist Financial increased their target price on Amgen from $325.00 to $327.00 and gave the company a “hold” rating in a report on Friday, May 1st. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amgen presently has a consensus rating of “Hold” and a consensus price target of $357.12.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.85% of the company’s stock.

Amgen Trading Up 0.8%

Shares of Amgen stock opened at $331.70 on Friday. The firm has a market capitalization of $179.01 billion, a price-to-earnings ratio of 23.08, a PEG ratio of 3.33 and a beta of 0.44. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29. The company has a debt-to-equity ratio of 5.65, a quick ratio of 0.90 and a current ratio of 1.26. The stock has a 50 day moving average of $355.12 and a 200 day moving average of $341.81.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the prior year, the business posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, research analysts predict that Amgen Inc. will post 22.36 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 3.0%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.15%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.